Surveillance For Clinical Use, Prescription Trends And Therapeutic Drug Monitoring (TDM) Of The Orphan Drug Rufinamide In Norway.

Trial Profile

Surveillance For Clinical Use, Prescription Trends And Therapeutic Drug Monitoring (TDM) Of The Orphan Drug Rufinamide In Norway.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Rufinamide (Primary)
  • Indications Epilepsy; Lennox-Gastaut syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Feb 2017 New trial record
    • 06 Dec 2016 Results presented at the 70th Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top